- $2.98bn
- $3.96bn
- $1.33bn
Annual cashflow statement for Haemonetics, fiscal year end - March 28th, USD millions except per share, conversion factor applied.
2022 April 2nd | 2023 April 1st | 2024 March 30th | 2025 March 29th | 2026 March 28th | |
|---|---|---|---|---|---|
| Period Length: | 52 W | 52 W | 52 W | 52 W | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 43.4 | 115 | 118 | 168 | 97.3 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 41.3 | 34.1 | 52.7 | 5.64 | 134 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -15.2 | 25.5 | -74.7 | -102 | -23.7 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | 172 | 273 | 182 | 182 | 293 |
| Capital Expenditures | -96.5 | -110 | -66.3 | -60.4 | -84.7 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 10.2 | -33.6 | -256 | -102 | -94.9 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -86.3 | -144 | -322 | -162 | -180 |
| Financing Cash Flow Items | -4.8 | -22.8 | -6.81 | -122 | -5.1 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -15.7 | -100 | 38.2 | 109 | -178 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 67.2 | 25 | -106 | 128 | -61.3 |